1. Home
  2. MCRB vs SAMG Comparison

MCRB vs SAMG Comparison

Compare MCRB & SAMG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • MCRB
  • SAMG
  • Stock Information
  • Founded
  • MCRB 2010
  • SAMG 2002
  • Country
  • MCRB United States
  • SAMG United States
  • Employees
  • MCRB N/A
  • SAMG N/A
  • Industry
  • MCRB Biotechnology: Pharmaceutical Preparations
  • SAMG Investment Managers
  • Sector
  • MCRB Health Care
  • SAMG Finance
  • Exchange
  • MCRB Nasdaq
  • SAMG Nasdaq
  • Market Cap
  • MCRB 165.3M
  • SAMG 151.1M
  • IPO Year
  • MCRB 2015
  • SAMG 2013
  • Fundamental
  • Price
  • MCRB $15.91
  • SAMG $16.21
  • Analyst Decision
  • MCRB Hold
  • SAMG
  • Analyst Count
  • MCRB 4
  • SAMG 0
  • Target Price
  • MCRB $73.67
  • SAMG N/A
  • AVG Volume (30 Days)
  • MCRB 245.4K
  • SAMG 19.9K
  • Earning Date
  • MCRB 11-12-2025
  • SAMG 10-30-2025
  • Dividend Yield
  • MCRB N/A
  • SAMG 5.18%
  • EPS Growth
  • MCRB N/A
  • SAMG N/A
  • EPS
  • MCRB 10.22
  • SAMG 0.87
  • Revenue
  • MCRB N/A
  • SAMG $124,451,000.00
  • Revenue This Year
  • MCRB N/A
  • SAMG $4.65
  • Revenue Next Year
  • MCRB N/A
  • SAMG $5.26
  • P/E Ratio
  • MCRB $1.62
  • SAMG $18.64
  • Revenue Growth
  • MCRB N/A
  • SAMG 4.13
  • 52 Week Low
  • MCRB $6.53
  • SAMG $13.54
  • 52 Week High
  • MCRB $24.67
  • SAMG $19.20
  • Technical
  • Relative Strength Index (RSI)
  • MCRB 44.26
  • SAMG 49.33
  • Support Level
  • MCRB $17.00
  • SAMG $15.81
  • Resistance Level
  • MCRB $24.67
  • SAMG $16.32
  • Average True Range (ATR)
  • MCRB 2.01
  • SAMG 0.27
  • MACD
  • MCRB -0.50
  • SAMG -0.02
  • Stochastic Oscillator
  • MCRB 15.94
  • SAMG 39.09

About MCRB Seres Therapeutics Inc.

Seres Therapeutics Inc is a microbiome therapeutics platform company operating in the United States. The company is engaged in developing biological drugs which are referred as ecobiotic microbiome therapeutics. The drugs discovered by the company are designed to restore health by repairing the function of a dysbiotic microbiome. The company focuses on implementing its microbiome therapeutics platform to develop ecobiotic microbiome therapeutics that treat dysbiosis in the colonic microbiome. SER-109, the company's product, is designed to prevent further recurrences of Clostridium difficile infection (CDI), a debilitating infection of the colon. In addition, the company is involved in developing SER-262, SER-287, and SER-401.

About SAMG Silvercrest Asset Management Group Inc.

Silvercrest Asset Management Group Inc is a wealth management firm focused on providing financial advisory and related family office services to ultra-high net-worth individuals and institutional investors. It advises clients on traditional investment strategies focused on equities, fixed income and cash as well as non-traditional investment strategies including hedge funds, private equity funds, real estate and commodities. It also provides clients with family office services and related administrative services, which include financial planning, tax planning and preparation, partnership accounting and fund administration, and consolidated wealth reporting. The company derives revenues principally from assets under management.

Share on Social Networks: